SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Sofinnova Investments, Inc.

CIK 0001631134 · 3000 Sand Hill Road, BUILDING 3-SUITE 150, Menlo Park, CA, 94025 · 650.681.8428

Reported Value
$1.8B
Q4 2023
Positions
64
Filings on Record
33
2019–present window
Filed
Feb 13, 2024
original filing

Summary

Sofinnova Investments, Inc. reported $1.8B in U.S.-listed holdings across 64 positions for Q4 2023.

The portfolio is heavily concentrated: Karuna Therapeutics alone accounts for 24.4% of reported value.

Compared with Q3 2023, the fund opened 16 new positions and exited 13.

Portfolio Metrics

Turnover
+28.6%
vs prior filed quarter
Top-10 Concentration
+65.3%
share of reported value
Largest Position
+24.4%
Karuna Therapeutics
New / Exited
16 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $803MQ4 ’18Q1 ’19: $1.0BQ2 ’19: $1.1BQ3 ’19: $1.1BQ4 ’19: $1.4BQ4 ’19Q1 ’20: $1.1BQ2 ’20: $1.6BQ3 ’20: $1.3BQ4 ’20: $1.7BQ4 ’20Q1 ’21: $1.7BQ2 ’21: $1.7BQ3 ’21: $1.7BQ4 ’21: $1.7BQ4 ’21Q1 ’22: $1.3BQ2 ’22: $1.2BQ3 ’22: $1.7BQ4 ’22: $1.7BQ4 ’22Q1 ’23: $1.6BQ2 ’23: $1.5BQ3 ’23: $1.6BQ4 ’23: $1.8BQ4 ’23Q1 ’24: $1.8BQ2 ’24: $1.8BQ3 ’24: $1.3BQ4 ’24: $1.4BQ4 ’24Q1 ’25: $1.5BQ2 ’25: $1.6BQ3 ’25: $1.8BQ4 ’25: $2.3BQ4 ’25Q1 ’26: $2.6Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 46.9%Other: 46.9%ADR: 6.2%
  • Common Stock · 46.9% · $838M
  • Other · 46.9% · $838M
  • ADR · 6.2% · $111M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LLYEli Lilly & CoNEW+64.5K64.5K+$38M$38M
KURAKura Oncology IncNEW+1.67M1.67M+$24M$24M
INCYIncyte CorpNEW+296.6K296.6K+$19M$19M
Pharvaris N VNEW+510.4K510.4K+$14M$14M
CABACabaletta Bio IncNEW+429.4K429.4K+$10M$10M
BSXBoston Scientific CorpNEW+131.0K131.0K+$8M$8M
PODDInsulet CorpNEW+19.0K19.0K+$4M$4M
IRWDIronwood Pharmaceuticals IncNEW+331.1K331.1K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Karuna Therapeutics IncCOM24.45%$437M1.38M
2RayzeBio IncCOM8.42%$150M2.42M
3NTRANatera Inchistory →COM5.43%$97M1.55M
4Ascendis Pharma A/SSPONSORED ADR5.31%$95M754.0K
5MRKMerck & Co Inchistory →COM5.23%$94M858.0K
6Aerovate Therapeutics IncCOM4.76%$85M3.76M
7AZNNAstraZeneca PLChistory →SPONSORED ADR3.21%$57M850.6K
8VERAVera Therapeutics Inchistory →CL A2.98%$53M3.47M
9IDYAIDEAYA Biosciences Inchistory →COM2.90%$52M1.46M
10IMGNEURImmunoGen Inchistory →COM2.57%$46M1.55M
11ISRGIntuitive Surgical Inchistory →COM2.40%$43M127.0K
12LLYEli Lilly & Cohistory →COM2.10%$38M64.5K
13CYTKCytokinetics Inchistory →COM1.94%$35M414.2K
14TCE2Celldex Therapeutics Inchistory →COM1.87%$33M844.0K
15CymaBay Therapeutics IncCOM1.87%$33M1.41M
16Immatics NVSHS1.75%$31M2.97M
17SNYSanofihistory →SPONSORED ADR1.67%$30M599.0K
18INBXUSDInhibrx Inchistory →COM1.64%$29M773.0K
19KVUEKenvue Inchistory →COM1.45%$26M1.21M
20KURAKura Oncology Inchistory →COM1.34%$24M1.67M
21SNDXSyndax Pharmaceuticals Inchistory →COM1.30%$23M1.08M
22Marinus Pharmaceuticals IncCOM1.08%$19M1.77M
23SYKStryker Corporationhistory →COM1.05%$19M62.8K
24INCYIncyte Corphistory →COM1.04%$19M296.6K
25GONGeron Corphistory →COM1.04%$19M8.81M
26Inozyme Pharma IncCOM1.02%$18M4.28M
27ELANElanco Animal Health Inchistory →COM1.00%$18M1.19M
28ARGXargenx SEhistory →SPONSORED ADR0.95%$17M44.7K
29YMABUSDY-mAbs Therapeutics Inchistory →COM0.84%$15M2.19M
30Pharvaris N VCOM0.80%$14M510.4K
31DYNDyne Therapeutics Inchistory →COM0.75%$13M1.01M
32AGENEURAgenus Inchistory →COM0.73%$13M15.66M
33YB4PSavara Inchistory →COM0.63%$11M2.38M
34MIRMMirum Pharmaceuticals Inchistory →COM0.58%$10M352.4K
35CABACabaletta Bio IncCOM0.55%$10M429.4K
36IMVTImmunovant IncCOM0.52%$9M222.6K
37BSXBoston Scientific CorpCOM0.42%$8M131.0K
38GPCRStructure Therapeutics IncSPONSORED ADS0.40%$7M174.8K
39MLTXMoonLake ImmunotherapeuticsCLASS A ORD0.38%$7M113.8K
40PODDInsulet CorpCOM0.23%$4M19.0K
41IRWDIronwood Pharmaceuticals IncCOM CL A0.21%$4M331.1K
42BOLT1EURBolt Biotherapeutics IncCOM0.17%$3M2.75M
43NXTCEURNextcure IncCOM0.17%$3M2.67M
44DC4Dexcom IncCOM0.14%$2M20.0K
45Cooper Cos IncCOM0.08%$2M4.0K
46MASI*Masimo CorpCOM0.08%$2M12.8K
47Nucana PLCSPONSORED ADR0.08%$1M4.68M
48Fusion Pharmaceuticals IncCOM0.06%$1M117.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.6B75May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.3B60Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.8B62Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B63Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.5B65May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.4B61Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.3B62Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.8B64Aug 15, 2024RESTATEMENTchanges · EDGAR ↗
Q1 2024$1.8B74May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.8B64Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.6B69Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.5B55Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.6B53May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.7B53Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.7B61Nov 8, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.2B61Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.3B64May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.7B72Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.7B70Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.7B67Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.7B64May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.7B69Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.3B157Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.6B186Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.1B150May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.4B135Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.1B167Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.1B163Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.0B164May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$803M137Feb 22, 2019RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.